Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 12, 2012, Pages 1842-1849

  Shaker, Olfat G ^a   Sadik, Nermin A H ^b  

^a Faculty of Medicine   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Hepatitis C patients; Interleukin 10; Interleukin 28; Single nucleotide polymorphisms

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; INTERLEUKIN 10; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERLEUKIN 10 GENE; INTERLEUKIN 28B GENE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; FORECASTING; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; ROC CURVE; TREATMENT OUTCOME;

EID: 84869774401     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07273.x     Document Type: Article

References (50)

1. Khan MH, Farrell GC, Byth K etal. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513-520.
2. El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International, 2009.
3. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J. Hepatol. 2000; 32 (Suppl. 1): 98-112.
4. Rehermann B, Nascimbeni M. Immunology of hepatitis b virus and hepatitis c virus infection. Nat. Rev. 2005; 5: 215-229.
5. Selzner N, Chen L, Borozan I etal. Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients. J. Hepatol. 2008; 48: 708-713.
6. Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin. Liver Dis. 2000; 20: 127-141.
7. McCaughan GW, George J. Fibrosis progression in chronic hepatitis C virus infection. Gut 2004; 53: 318-321.
8. Fukuda R, Ishimura N, Ishihara S etal. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996; 16: 390-399.
9. Osna N, Silonova G, Vilgert N etal. Chronic hepatitis C: T-helper1/T-helper2 imbalance could cause virus persistence in peripheral blood. Scand. J. Clin. Lab. Invest. 1997; 57: 703-710.
10. Kotenko SV, Gallagher G, Baurin VV etal. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003; 4: 69-77.
11. Sheppard P, Kindsvogel W, Xu W etal. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003; 4: 63-68.
12. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J. Leukoc. Biol. 2004; 76: 314-321.
13. Brand S, Dambacher J, Beigel F etal. IL-22- mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 292: G1019-1028.
14. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27: 647-659.
15. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996; 24: 6-9.
16. Jia HY, Du J, Zhu SH etal. The roles of serum IL-18, IL-10, TNF-alpha and sIL-2R in patients with chronic hepatitis C. Hepatobiliary Pancreat. Dis. Int. 2002; 1: 378-382.
17. Bidwell J, Keen L, Gallagher G etal. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun. 1999; 1: 3-19.
18. Nelson DR, Lauwers GY, Lau JYN, Davis G. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon non responders. Gasteroenterology 2000; 118: 655-660.
19. Constantini PK, Wawrzynowicz-Syczewska M, Clare M etal. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002; 22: 404-412.
20. Lio D, Caruso C, Di Stefano R etal. Almasio; IL-10 and TNF-α polymorphisms and the recovery from HCV infection. Hum. Immunol. 2003; 64: 674-680.
21. Sobue S, Nomura T, Ishikawa T etal. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J. Gastroenterol. 2001; 36: 544-551.
22. Thompson AJ, Muir AJ, Sulkowski MS etal. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. J. Gastroenterol. 2010; 139: 120-129.
23. Rauch A, Kutalik Z, Descombes P etal. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
24. Kempuraj D, Donelan J, Frydas S etal. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities. Int. J. Immunopathol. Pharmacol. 2004; 17: 103-106.
25. Abbas Z, Moatter T, Hussainy A, Jafri W. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J. Gastroenterol. 2005; 11: 6656-6661.
26. Selzner N, McGilvray I. Can genetic variations predict HCV treatment outcomes? J. Hepatol. 2008; 49: 494-497.
27. Hoffmann SC, Stanley EM, Cox ED etal. Ethnicity greatly influences cytokine gene polymorphism distribution. Am. J. Transplant. 2002; 2: 560-567.
28. Kurbanov F, Abdel-Hamid M, Latanich R etal. Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort. J. Infect. Dis. 2011; 204: 1391-1394.
29. Barrett S, Collins M, Kenny C, Ryan E, Keane CO, Crowe J. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin- 10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J. Med. Virol. 2003; 71: 212-218.
30. Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J. Hepatol. 2002; 36: 271-277.
31. Chuang JY, Yang SS, Lu YT etal. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig. Liver Dis. 2009; 41: 424-430.
32. Zhang LZ, Zhang TC, Pan FM, Zhang ZH, Li X. Interleukin-10 gene polymorphisms in association with susceptibility to chronic hepatitis C virus infection: a meta-analysis study. Arch. Virol. 2010; 155: 1839-1842.
33. Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Hohler T. Differential regulation of interleukin-10 production by genetic and environmental factors-a twin study. Genes Immun. 2002; 3: 407-413.
34. Zhang P, Chen Z, Chen F etal. Expression of IFN-gamma and its receptor alpha in the peripheral blood of patients with chronic hepatitis C. Chin. Med. J. (Engl) 2004; 117: 79-82.
35. Gramenzi A, Andreone P, Loggi E etal. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J. Viral Hepat. 2005; 12: 525-530.
36. Chen TY, Hsieh YS, Wu TT etal. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl. Res. 2007; 150: 116-121.
37. Ferrari C, Valli A, Galati L etal. T-cell response to structural and nonstructural hepatitis C variants in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19: 286-295.
38. Lasarte JJ, García-Granero M, López A etal. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 1998; 28: 815-822.
39. Koziel MJ. Cellular immune responses against hepatitis C virus. Clin. Infect. Dis. 2005; 41: 25-31.
40. Barrat FJ, Cua DJ, Boonstra A etal. In vitro generation of interleukin 10-producing regulatory CD4 (1) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 2002; 195: 603-616.
41. Sher A, Gazzinelli RT, Oswald IP etal. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol. Rev. 1992; 127: 183-204.
42. Gerlach JT, Diepolder HM, Jung MC etal. Recurrence of hepatitis C virus after loss of virus-specific CD4(1) T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933-941.
43. Sarih M, Bouchrit N, Bebslimane A. Different cytokine profiles of peripheral blood mononuclear cells from patients with persistent and self-limited hepatitis C virus infection. Immunol. Lett. 2000; 74: 117-120.
44. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30: 526-530.
45. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
46. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-1109.
47. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-429.
48. Haller O, Kocks G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 2006; 344: 119-130.
49. Stoltz M, Ahlm C, Lundkvist A, Klingström J. Lambda interferon (IFN-lambda) in serum is decreased in hantavirus-infected patients, and in vitro-established infection is insensitive to treatment with all IFNs and inhibits IFN-gamma-induced nitric oxide production. J. Virol. 2007; 81: 8685-8691.
50. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009; 41: 1100-1104.